Key Takeaways
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the pricing of an upsized public offering of its common stock, expecting gross proceeds of approximately $700 million to fund operations and clinical trials.
The offering was managed by a syndicate of banks with Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acting as joint book-running managers.
The biopharmaceutical company is selling 9,859,155 shares at $71.00 per share. Underwriters have a 30-day option to purchase up to an additional 1,478,873 shares of common stock at the same price, according to a company statement.
The capital raise, expected to close May 8, will increase the number of shares outstanding, likely causing short-term pressure on the stock from dilution for existing shareholders.
The successful capital raise could strengthen the company's financial position to advance its pipeline of potential new medicines for diseases of cardiac muscle dysfunction. Investors will watch for the effective use of capital in funding trials for drugs like omecamtiv mecarbil and ulacamten.
This article is for informational purposes only and does not constitute investment advice.
